Pancreatic  cancer is notoriously difficult to treat — and in many cases leads to death just months after diagnosis. So it is no surprise that this headline created a stir:  In a recent study , a new drug, daraxonrasib, was able to double the survival time of patients with pancreatic cancer. Compared with patients who underwent chemotherapy, those treated with daraxonrasib not only lived longer, but also reported a better quality of life. The treatment also appeared to cause fewer severe side